ARCA Biopharma Inc. Daily Stock Analysis

Daily Stock Analysis, ABIO, ARCA Biopharma Inc, priceseries

ARCA Biopharma Inc. Daily Stock Analysis
Stock Information
Open
1.99
Close
2.07
High
2.10
Low
1.95
Previous Close
2.04
Daily Price Gain
0.03
YTD High
2.32
YTD High Date
Jan 3, 2022
YTD Low
1.71
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.23
YTD Gain
-10.00%
52 Week High
4.36
52 Week High Date
Mar 11, 2021
52 Week Low
1.71
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-1.91
52 Week Gain
-47.99%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2018
26.10
Jan 17. 2018
28.08
9 Trading Days
7.58%
Link
LONG
May 8. 2018
9.47
May 29. 2018
10.38
14 Trading Days
9.68%
Link
LONG
Jul 10. 2018
10.47
Jul 11. 2018
11.00
1 Trading Days
5.01%
Link
LONG
Sep 28. 2018
10.08
Oct 8. 2018
11.81
6 Trading Days
17.18%
Link
LONG
Mar 4. 2019
8.28
Mar 6. 2019
9.09
2 Trading Days
9.78%
Link
LONG
May 7. 2019
12.58
May 10. 2019
13.21
3 Trading Days
5.01%
Link
LONG
Sep 9. 2019
5.57
Sep 17. 2019
5.95
6 Trading Days
6.85%
Link
LONG
Apr 13. 2020
3.39
Apr 22. 2020
3.75
7 Trading Days
10.88%
Link
LONG
May 27. 2020
3.95
Jun 4. 2020
8.39
6 Trading Days
112.53%
Link
LONG
Jan 11. 2021
4.29
Jan 25. 2021
4.52
9 Trading Days
5.43%
Link
LONG
Feb 3. 2021
4.54
Feb 17. 2021
4.83
9 Trading Days
6.37%
Link
Company Information
Stock Symbol
ABIO
Exchange
NasdaqCM
Company URL
http://www.arcabiopharma.com
Company Phone
720-940-2200
CEO
Michael R. Bristow
Headquarters
Colorado
Business Address
11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER, CO 80020
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000907654
About

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company's business combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, GencaroTM is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Description

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in patients with heart failure and left ventricular with reduced left ventricular ejection fraction. The company also engages in developing recombinant Nematode Anticoagulation Protein c2, a therapy for the disease syndrome caused by infection from hemorrhagic fever viruses and other pathogens. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3 clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading